Company intelligence / Profile preview

Amylyx Pharmaceuticals

Cambridge, Massachusetts, United Statesamylyx.com ↗

Ownership: Public · AMLX
Development stage: Commercial

Overview

Amylyx had a marketed drug (AMX0035/Relyvrio/Albrioza) for ALS that was withdrawn in April 2024 after Phase 3 trial failed to show efficacy. Currently advancing multiple clinical programs including AMX0114 (Phase 1 for ALS with first participant dosed in April 2025) and avexitide (Phase 3-ready for PBH with FDA Breakthrough Therapy Designation)[2][7][9][10]

Therapeutic areas: EndocrinologyRare DiseasesNeurology
Modalities: Small moleculesantisense oligonucleotides (ASO)peptides
Industry: Biotech

Drug pipeline

3 assets

AMX0114

2 more assets in the full pipeline.

Request access →

Partnerships

Gubra (for development of novel long-acting GLP-1 receptor antagonist)

Financials

Market cap: $3.8B
Total revenue: $0
Enterprise value: $3.5B

Beyond the preview

Go deeper on Amylyx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amylyx Pharmaceuticals.

Explore the full profile